Press releases

2025/21/10 - 18:02 ABIONYX Pharma Announces Landmark Validation: A Study published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis pdf
2025/25/09 - 18:30 2025 Half-Year financial results pdf
2025/28/08 - 19:00 ABIONYX Pharma provides an update on its activity and cash position for the 2nd quarter 2025 pdf
2025/27/08 - 19:37 ABIONYX Pharma announces the start of discussions with a major player in the field of sepsis for a strategic partnership pdf
2025/27/06 - 19:00 ABIONYX Pharma announces approval of all resolutions put to the vote at its Combined General Meeting pdf
2025/28/05 - 18:00 ABIONYX Pharma provides an update on its activity and cash position for the 1st quarter 2025 pdf
2025/06/05 - 20:01 Monthly statement of total voting rights and shares forming the company’s share capital pdf
2025/21/03 - 07:30 CIC Market Solutions initiates buy coverage of ABIONYX Pharma pdf
2025/17/03 - 18:00 Availability of the Universal Registration Document for the year 2024 pdf
2025/05/03 - 07:30 ABIONYX Pharma announces its 2024 full-year results pdf
2025/28/02 - 07:30 World Rare Disease Day: ABIONYX renews its commitment to treat LCAT Deficiency (Norum's disease) and provides an update on its advances pdf
2025/27/02 - 19:04 ABIONYX Pharma provides an update on its business and cash position for the 4th quarter of 2024 pdf
2025/20/02 - 07:30 ABIONYX Pharma, winner of the France 2030 Plan’s “i-Démo” call for projects, awarded €8.7 million from the French government to fight against Sepsis, the 3rd leading cause of death worldwide pdf
2025/13/01 - 18:00 ABIONYX Pharma announces its financial calendar for the year 2025 pdf
2024/29/11 - 20:00 ABIONYX Pharma announces the approval of all resolutions put to the vote at its Combined General Meeting on November 28, 2024 pdf
2024/14/11 - 19:00 ABIONYX Pharma provides an update on its business and cash position for the third quarter of 2024 pdf
2024/07/11 - 07:00 ABIONYX Pharma announces the main resolutions proposed at the next Combined General Meeting on November 28, 2024, and the availability of related documents pdf
2024/24/10 - 19:30 ABIONYX Pharma RACERS study clinical results in brain-fog selected for Poster Presentation at the American Society of Nephrology (ASN) 2024 Annual Meeting "Kidney Week" pdf
2024/21/10 - 20:00 ABIONYX Pharma received positive feedback from the EMA for CER-001 in LCAT Deficiency pdf
2024/26/09 - 18:30 ABIONYX Pharma announces its 2024 Half-Year financial results pdf
2024/22/08 - 18:00 ABIONYX Pharma provides an update on its business and cash position for the 1st half of 2024 pdf
2024/01/07 - 08:00 ABIONYX carries out successfully a capital increase with cancellation of preferential subscription rights for the benefit of a category of persons through the issue of shares with warrants for an amount of c.€3.4 million pdf
2024/27/06 - 19:00 ABIONYX Pharma announces unanimous approval of all resolutions put to the vote at its Combined General Meeting pdf
2024/19/06 - 19:30 ABIONYX decides on a capital increase with cancellation of preferential subscription rights for the benefit of a category of persons through the issue of shares with warrants for an amount of c.€3.4 million pdf
2024/13/06 - 19:30 ABIONYX Pharma has completed a successful pre-IND meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis pdf
2024/16/05 - 18:00 ABIONYX Pharma provides an update on its activity and cash position for the 1st quarter 2024 pdf
2024/02/05 - 18:00 Availability of the Universal Registration Document for the year 2023 pdf
2024/14/03 - 18:00 Bpifrance supports the development of CER-001 in ophthalmology with a nearly €1 million non-dilutive innovation grant pdf
2024/11/03 - 07:30 ABIONYX Pharma announces its 2023 full-year financial results pdf
2024/07/03 - 19:00 ABIONYX Pharma announces its financial calendar for the year 2024 pdf
2024/29/02 - 18:08 ABIONYX Pharma provides an update on its activity and cash position for the 4th quarter 2023 pdf
2024/16/02 - 08:00 Clarification about clinical results from the phase 3 of apoA-I study, CSL112 pdf
2024/15/02 - 18:00 Clinical results of the Phase 3 AEGIS-II study: - Validation of ABIONYX Pharma's strategic repositioning in severe diseases with short apoA-I treatment - No safety or tolerability problems in 18,000 patients pdf
2024/08/01 - 18:03 ABIONYX Pharma appoints Rob Scott, MD, as Chief Medical Officer and Head of R&D pdf
2023/18/12 - 18:00 ABIONYX Pharma successfully manufactures a third batch of recombinant human apoA-I CER-001 using a new, innovative and robust industrial bioprocess pdf
2023/23/11 - 19:23 ABIONYX Pharma presents preclinical results for CER-001 in Brain Fog, at the 1st International Scientific Congress on Brain-Kidney Interaction in Naples on November 23-24, 2023 pdf
2023/21/11 - 07:00 ABIONYX Pharma announces new positive results in a uveitis model for the strategic development of the first class of biomedicines in ophthalmology based on its recombinant apoA-I pdf
2023/16/11 - 18:00 ABIONYX Pharma provides an update on its activity, its revenue and its cash position for the third quarter of 2023 pdf
2023/02/11 - 18:55 Poster RACERS - CER-001, an Engineered High-Density Lipoprotein, shows beneficial pleiotropic effects in patients with sepsis in RACERS: a Phase 2a randomized clinical tria pdf
2023/02/11 - 17:56 ABIONYX Pharma RACERS study data in sepsis presented at the American Society of Nephrology (ASN) 2023 Annual Meeting "Kidney Week" pdf
2023/16/10 - 07:00 ABIONYX Pharma RACERS study in sepsis selected for Late-Breaking Clinical Results Poster Presentation at the American Society of Nephrology (ASN) 2023 Annual Meeting "Kidney Week" pdf
2023/06/10 - 07:30 ABIONYX Pharma completes a capital increase in favor of categories of persons pdf
2023/26/09 - 20:00 ABIONYX Pharma announces its 2023 Half-Year financial results pdf
2023/12/09 - 20:00 World Sepsis Day: ABIONYX Pharma confirms its commitment to sepsis, a global public health issue pdf
2023/17/08 - 18:00 ABIONYX Pharma provides an update on its business and cash position for the first half of 2023 pdf
2023/26/07 - 18:30 ABIONYX Pharma successfully manufactures a second batch of recombinant human ApoA-I CER-001 using a new, innovative and robust industrial bioprocess pdf
2023/13/07 - 07:30 ABIONYX Pharma announces the appointment of Laurent Guerci as Chief Digital & Innovation Officer pdf
2023/10/07 - 18:00 ABIONYX Pharma announces a new Compassionate Access Authorization (CAA) for CER-001 in the rare disease LCAT deficiency or Norum disease in Europe pdf
2023/29/06 - 18:00 ABIONYX Pharma announces unanimous approval of all resolutions put to the vote at its Combined General Meeting pdf
2023/29/05 - 20:15 ABIONYX Pharma provides further details on the setting up of its equity-linked financing facility pdf
2023/23/05 - 20:30 ABIONYX Pharma accelerates its development by launching a new biomanufacturing campaign based on the recently announced robust innovative process supported by an equity-linked financing facility pdf
2023/17/05 - 18:30 ABIONYX Pharma provides an update on its activity and its cash position for the first quarter 2023 pdf
2023/10/05 - 18:30 ABIONYX Pharma announces the successful manufacturing of the first batch of CER-001 with recombinant human ApoA-I using a new innovative and robust industrial bioprocess pdf
2023/02/05 - 18:00 Availability of the Universal Registration Document for the year 2022 pdf
2023/31/03 - 18:45 ABIONYX Pharma announces its strategy in ophthalmology and new positive preclinical results for the deployment of two innovative technology platforms: apotherapy and biovectorization pdf
2023/29/03 - 18:36 ABIONYX Pharma announces its 2022 full-year financial results pdf
2023/28/02 - 18:00 ABIONYX Pharma provides an update on its activity and its cash position for the 4th quarter 2022 pdf
2023/03/02 - 19:30 Press release pdf
2023/16/01 - 12:00 ABIONYX Pharma Reports Positive Results from Phase 2a Pilot Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury pdf
2023/13/01 - 07:30 ABIONYX Pharma announces its financial agenda for the year 2023 pdf
2022/17/11 - 18:30 ABIONYX Pharma announces its cash position and provides an activity update on the 3rd quarter 2022 pdf
2022/04/10 - 18:00 ABIONYX Announces Final Patient Enrollment in Phase 2a Clinical Trial with CER-001, Bio-HDL for the Treatment of Patients with Sepsis at High Risk of Developing Acute Kidney Injury pdf
2022/29/09 - 18:30 ABIONYX Pharma announces its 2022 half-year financial results pdf
2022/18/08 - 17:45 ABIONYX Pharma provides an update on its business and cash position for the first half of 2022 pdf
2022/04/07 - 17:45 ABIONYX Pharma announces the reinitiation of coverage of its stock by TPICAP Midcap pdf
2022/30/06 - 18:00 Combined General Meeting of June 28, 2022 pdf
2022/19/05 - 18:00 ABIONYX Pharma provides an update on its business and cash position for the first quarter of 2022 pdf
2022/29/04 - 18:00 Availability of the Universal Registration Document for the year 2021 pdf
2022/28/04 - 18:00 Annual results 2021 pdf
2022/07/04 - 07:30 ABIONYX Pharma Reports Positive Interim Results from Phase 2a Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury pdf
2022/29/03 - 17:45 ABIONYX Pharma Receives FDA Orphan Drug Designation (ODD) for CER-001 for the Treatment of LCAT Deficiency Presenting as Kidney Dysfunction and/or Ophthalmologic Disease pdf
2022/24/03 - 18:00 ABIONYX announces positive clinical findings for CER-001 in treating COVID-19, published in Biomedecines, demonstrating that CER-001 limits inflammation effects pdf
2022/24/02 - 18:00 ABIONYX Pharma provides an update on its business and cash position for Q4 2021 pdf
2022/31/01 - 17:45 ABIONYX Pharma announces its financial agenda for the year 2022 pdf
2022/03/01 - 18:00 ABIONYX Pharma announces that the French Drug Safety Agency (Agence Nationale de Sécurité du Médicament or ANSM) has granted a Compassionate Access Authorization for the bio-HDL (CER-001) in COVID-19 disease pdf
2021/06/12 - 07:30 ABIONYX Pharma announces the completion of a contribution in kind to the company of 100% of the capital of IRIS Pharma Holding, fully compensated by the issue of new shares at a price of €3.60 per share to become a specialist of bioproducts in ophthalmolo pdf
2021/02/12 - 07:30 ABIONYX announces the success of its capital increase in cash by private placement at a price of €3.60 per share pdf
2021/17/11 - 19:09 ABIONYX announces the signing of an agreement for the contribution of 100% of the capital of IRIS Pharma Holding, fully remunerated by the issuance of new ABIONYX shares at a fixed price of 3.60 euros per share pdf
2021/15/11 - 07:30 ABIONYX Announces New Positive Clinical Results for CER-001 in kidney disease associated with LCAT deficiency Published in The Journal of Internal Medicine pdf
2021/04/11 - 18:45 ABIONYX Pharma announces its cash position and provides an activity update for the 3rd quarter 2021 pdf
2021/11/10 - 18:45 ABIONYX Pharma initiates discussions with IRIS Pharma, a world leader in preclinical and clinical ophthalmology research, with a view to a possible strategic deal pdf
2021/07/10 - 07:30 ABIONYX Pharma announces positive preclinical results in a model of uveitis and launches the strategic development of the first class of biomedicines in ophthalmology based on its bio-HDL pdf
2021/09/09 - 18:45 ABIONYX Pharma announces its 2021 half year financial results and provides an update on its development activities pdf
2021/05/08 - 19:00 Gross cash position and business update for the first half of 2021 pdf
2021/28/07 - 07:30 ABIONYX Pharma receives positive opinion from EMA within the framework of the Orphan Drug Designation process for CER-001 for the rare disease LCAT Deficiency pdf
2021/16/06 - 18:00 ABIONYX Pharma presents its “raison d'être” and states in its articles of association pdf
2021/08/06 - 07:30 ABIONYX Announces First Patient Enrolled in Phase 2a Clinical Study with CER-001, the Bio-HDL for the Treatment of septic patients at high risk of developing Acute Kidney Injury pdf
2021/06/05 - 19:14 Financial Highlights and business review for the first quarter of 2021 pdf
2021/27/04 - 18:00 Availability of the Universal Registration Document for the year 2020 pdf
2021/26/04 - 18:00 Convening of the 2021 Combined General Meeting pdf
2021/25/03 - 07:54 ABIONYX announces the signing of a strategic partnership with GTP Biologics (Fareva Group) and V-Nano (VBI Therapeutics group) for the bioproduction of the bio-HDL CER-001 in France pdf
2021/02/03 - 07:34 Positive Clinical Results From CER-001 in an ultrarare kidney disease Published in The Annals of Internal Medicine pdf
2021/25/02 - 19:03 Annual results 2020 pdf
2021/04/02 - 18:07 ABIONYX Pharma provides an update on its cash position and the start of its clinical activities in Q4 2020 pdf
2021/25/01 - 08:00 ABIONYX Pharma announces its financial agenda for the year 2021 pdf
2020/23/12 - 07:30 ABIONYX initiates a Phase 2a clinical trial with CER-001 in septic patients at high risk of developing Acute Kidney Injury pdf
2020/15/12 - 19:01 Publication of pre-clinical data in the journal Metabolism demonstrating that CER-001 improves lipid profile and kidney function for an ultra-rare kidney disease pdf
2020/25/11 - 19:03 ABIONYX announces the observation of positive therapeutic signals in Temporary Authorizations for Use (ATUn) in France and Italy for an ultra-rare kidney disease pdf
2020/22/10 - 18:21 ABIONYX announces its cash position and provides an activity update for the 3rd quarter 2020 pdf
2020/14/10 - 19:24 ABIONYX announces the success of a capital increase for the benefit of persons belonging to specific categories pdf
2020/02/10 - 20:38 ABIONYX clarifies its strategy and announces the launch of a capital increase for the benefit of persons belonging to specific categories pdf
2020/10/09 - 18:37 Availability of the half-year financial report 2020 (French) pdf
2020/10/09 - 18:36 2020 Half-year results pdf
2020/23/07 - 18:05 Gross cash position for the first semester of 2020 pdf
2020/27/04 - 17:50 Availability of the Universal Registration Document for the year 2019 pdf
2020/23/04 - 20:17 Gross cash position and business review for the first quarter of 2020 pdf
2020/10/03 - 19:19 2019 annual results pdf
2020/04/02 - 20:19 Cash position and activity update for Q4 2019 pdf
2020/28/01 - 18:00 ABIONYX Pharma announces its financial agenda for the year 2020 pdf
2020/08/01 - 08:00 ABIONYX Pharma announces a named patient Temporary Authorization for Use (ATUn) for CER-001 in France pdf
2020/03/01 - 14:48 Resignation of a member of the Board of Directors pdf
2019/24/10 - 18:00 Cash position and activity update for Q3 2019 pdf
2019/13/09 - 08:00 Message from the Board of Directors pdf
2019/09/09 - 08:00 Cyrille Tupin appointed CEO pdf
2019/06/09 - 07:00 2019 Half-year results pdf
2019/27/08 - 18:30 Change of name and stock symbol/mnemonic of ABIONYX Pharma shares (formerly CERENIS Therapeutics) as of August 29, 2019 pdf
2019/26/08 - 20:20 ABIONYX Pharma announces appointment of a new member to the Board pdf
2019/18/07 - 19:29 CERENIS Therapeutics announces cash position and activity update for Q2 2019 pdf
2019/24/06 - 22:25 Cerenis Therapeutics announces the results of the Annual Combined General Meeting of Shareholders pdf
2019/14/06 - 19:59 Cerenis announces the success of a capital increase for the benefit of persons belonging to specific categories pdf
2019/13/06 - 21:00 Cerenis announces the launch of a capital increase for the benefit of persons belonging to specific categories pdf
2019/18/04 - 18:02 Cash position and activity update for Q1 2019 pdf
2019/27/03 - 18:21 Cerenis Therapeutics and H4Orphan Pharma enter into exclusive negotiations to consider a strategic merger pdf
2019/24/01 - 19:12 2018 Annual Results and clinical update pdf
2019/23/01 - 18:15 2019 Financial agenda pdf
2018/20/12 - 19:35 Results of the Phase I study of repeated and increasing doses to assess CER-209 in NASH/NAFLD pdf
2018/19/12 - 06:21 CERENIS Therapeutics’ Board of Directors appoints Richard Pasternak as CEO and Cyrille Tupin as Deputy CEO pdf
2018/17/12 - 18:09 Final results of TARGET PHASE II study demonstrate the ability of CER-001, an HDL mimetic, to target tumor in patients with esophageal cancer pdf
2018/05/12 - 08:01 CERENIS announces the results of TANGO, a Phase III clinical study evaluating CER-001 in patients with HDL deficiency pdf
2018/21/11 - 08:02 Statement following the evolution of the Cerenis share price pdf
2018/25/10 - 18:02 Cerenis Therapeutics - Announces its cash position for Q3 2018 and highlights the progress made over the period and key perspectives for the end of 2018 pdf
2018/22/10 - 18:07 CERENIS to present new data validating HDL targeted drug delivery in the field of oncology and immuno-oncology at the 30th EORTC/NCI/AACR symposium pdf
2018/10/09 - 07:02 2018 Half-Year Results pdf
2018/31/07 - 18:06 Cerenis announces today the appointment of Barbara Yanni to its Board of Directors as an Independent Director pdf
2018/26/07 - 07:48 Cerenis announces financing from investment funds, management, its board of directors and its oncology scientific advisory board pdf
2018/18/07 - 18:54 Cash position and activity update for H1 2018 and key perspectives for the end of 2018 pdf
2018/25/06 - 18:53 First results of TARGET PHASE II study demonstrate the ability of CER-001, an HDL mimetic, to target tumor in patients with esophageal cancer pdf
2018/29/05 - 07:30 CERENIS Therapeutics and University of North Texas Health Science Center announce a strategic initiative to develop new HDL-based pharmaceutical products pdf
2018/07/05 - 17:55 Cerenis to attend 2018 HDL Workshop (adjacent to ATVB|PVD Scientific Sessions) pdf
2018/02/05 - 18:10 Seasoned Scientific Experts and Strategic Pharmaceutical Industry Veterans Join Cerenis’ Scientific Advisory Board in Oncology pdf
2018/23/04 - 22:19 Publication of 2017 Registration Document pdf
2018/19/04 - 19:01 Cash position and activity update for Q1 2018 pdf
2018/07/03 - 19:25 Approval to launch the Phase I Study of repeated and increasing doses to assess CER-209 in NASH/NAFLD pdf
2018/01/02 - 19:32 2017 Annual Results and Update on TANGO pdf
2018/25/01 - 18:17 Cash position and activity update for Q4 2017 pdf
2018/23/01 - 18:28 2018 Financial Agenda pdf
2017/22/11 - 08:14 Cerenis - First patients enter TARGET study, recently initiated by Cerenis Therapeutics to evaluate HDL nanoparticles in patients with esophageal cancer pdf
2017/08/11 - 07:52 CERENIS Therapeutics acquires LYPRO Biosciences expanding its HDL strategy into immuno-oncology and chemotherapeutic drug delivery pdf
2017/26/10 - 18:00 Cash position and activity update for Q3 2017 pdf
2017/18/10 - 17:52 Completion of patient enrollment in the Phase 3 study, TANGO, evaluating CER-001 in HDL genetic deficiency pdf
2017/12/09 - 18:30 2017 Half-Year Results pdf
2017/04/09 - 18:01 Cerenis Therapeutics announces participation at the 19th annual Rodman & Renshaw global investment conference in New York city, September 10-12, 2017 pdf
2017/20/07 - 18:20 Cash position and activity update for H1 2017 pdf
2017/20/06 - 10:35 Bpifrance supports the clinical development of CER-209 in NAFLD /NASH with a €0.75 million payment for innovation pdf
2017/07/06 - 19:10 Positive results from the CER-209 Phase I Single Dose Tolerance study for NAFLD and NASH pdf
2017/28/04 - 20:41 Publication of 2016 Registration Document pdf
2017/20/04 - 18:50 Cash position and update on clinical developments for Q1 2017 pdf
2017/18/04 - 07:56 Cerenis Therapeutics announces the initiation of the Phase 1 clinical study with CER-209 in NAFLD and NASH pdf
2017/20/03 - 07:58 Cerenis Therapeutics announces that CARAT Phase 2 Study data on CER-001 have been presented at ACC annual meeting 2017 pdf
2017/01/03 - 17:21 Cerenis Therapeutics Announces Top line Results of CARAT Phase II Study pdf
2017/17/02 - 18:02 2016 Annual Results pdf
2017/03/02 - 17:58 2017 Financial Calendar pdf
2017/19/01 - 19:07 Clinical progress, cash position and revenue for Q4 2016 pdf
2016/15/12 - 21:42 Cerenis Therapeutics Receives FDA IND Approval to Begin Studies with CER-209 in NAFLD and NASH pdf
2016/08/11 - 07:09 Cerenis Therapeutics Announces Last Patient Dosed in CARAT Phase II Study with CER-001 in Post-Acute Coronary Syndrome Patients pdf
2016/07/11 - 09:15 Cash position and revenue for Q3 2016 pdf
2016/05/09 - 17:51 2016 Half-Year Results - Solid cash position of €33 million and major scientific results pdf
2016/01/09 - 07:00 Positive safety and tolerability profile of CER-001 presented at the European Society of Cardiology (ESC) Congress 2016 pdf
2016/30/08 - 08:00 Completion of patient enrolment in the CARAT study – meeting the clinical schedule pdf
2016/28/07 - 07:44 Cash position and revenue for the first semester of 2016 pdf
2016/02/06 - 07:44 Publication of the LOCATION clinical study results in the renowned scientific journal of the European Atherosclerosis Society (EAS) pdf
2016/03/05 - 07:13 Cash position and revenue for the 1st quarter of 2016 pdf
2016/18/04 - 18:06 Cerenis Therapeutics announces the publication of an initiation of coverage report by PORTZAMPARC, within the framework of the share’s market coverage pdf
2016/08/03 - 18:18 Cerenis Therapeutics announces its participation to the 28th ROTH Capital Partners annual conference pdf
2016/03/03 - 18:28 Publication of an initiation of coverage report by KEPLER CHEUVREUX, within the framework of the share’s market coverage pdf
2016/01/03 - 19:01 2015 annual results pdf
2016/25/02 - 07:50 Cerenis Therapeutics featured prominently at the 25th Conference of the ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER (APASL) pdf
2016/16/02 - 07:30 Cash position and revenue for 2015 pdf
2016/29/01 - 10:57 Catalent Biologics And Cerenis Therapeutics Announce Phase III Trial Of CER-001 In Europe And North America Leveraging GPEx® Cell Line Technology www
2016/26/01 - 20:15 2016 Financial calendar pdf
2015/17/12 - 19:45 Cerenis Therapeutics admitted to the SRD (Defered Settlement Service) “Long-only” pdf
2015/10/12 - 07:27 First patient enters Phase III TANGO clinical trial to evaluate efficacy to regress atherosclerosis and safety of CER-001 in patients with Familial Primary HypoAlphalipoproteinemia (FPHA) pdf
2015/23/11 - 18:29 Cerenis' flagship product named one of 2015's most promising cardiovascular projects at the American Therapeutic Area Partnerships conference pdf
2015/12/11 - 18:25 Cash position and revenue for Q3 2015 pdf
2015/10/11 - 07:41 New Data for CER-001 presented in key Oral Session at AMERICAN HEART ASSOCIATION (AHA) CONFERENCE 2015 pdf
2015/03/11 - 08:08 CER-001: Analysis of clinical results to be presented at the American Heart Association Scientific Congress, on November 9, 2015 in Orlando, UNITED-STATES pdf
2015/17/09 - 08:01 Cerenis Therapeutics is joining the Euronext indexes CAC® Small, CAC® Mid & Small and CAC® All-Tradable pdf
2015/08/09 - 08:03 First patients enter phase II CARAT trial to assess reduction in atherosclerotic plaque using CER-001 in post Acute Coronary Syndrome (ACS) patients pdf
2015/07/09 - 17:53 Press release for the availability of preparatory documents for the shareholder meeting pdf
2015/04/09 - 07:54 Publication of positive preclinical data in the world-renowned scientific journal PLOS ONE pdf
2015/25/08 - 18:12 2015 Half-Year Results pdf
2015/21/07 - 07:53 Revenue and cash position for H1 2015 pdf
2015/15/07 - 02:00 Cerenis Therapeutics announces the results of the LOCATION study pdf
2015/09/06 - 02:00 Cerenis Therapeutics announces new Board members pdf
2015/26/05 - 17:27 CERENIS THERAPEUTICS featured prominently at the INTERNATIONAL SYMPOSIUM ON ATHEROSCLEROSIS (IAS) pdf
2015/13/05 - 17:27 Cash position and revenue for Q1 2015 pdf
2015/25/03 - 16:27 Outstanding success of Cerenis Therapeutics’ IPO with €53.4 million raised on Euronext Paris pdf
2015/12/03 - 16:27 CERENIS THERAPEUTICS launches its IPO on the Euronext regulated market in Paris pdf
2015/09/02 - 16:27 CERENIS THERAPEUTICS announces the appointment of a new Director of Clinical Research and new members to the Board pdf
2014/03/09 - 17:27 CERENIS THERAPEUTICS receives EMA Orphan Drug Designations for CER-001 for the treatment of ApoA-I and ABCA-1 deficiencies pdf
2014/03/09 - 17:27 CERENIS THERAPEUTICS appoints R. Pasternak as Chairman of Cerenis Board September 3, 2014 pdf
2014/02/06 - 17:27 CERENIS THERAPEUTICS reports two positive Phase II Studies for HDL mimetic CER-001 at EA pdf